Annual CFF
$15.91 M
+$15.90 M+265055.00%
01 December 2023
Summary:
TransCode Therapeutics annual cash flow from financing activities is currently $15.91 million, with the most recent change of +$15.90 million (+265055.00%) on 01 December 2023. During the last 3 years, it has fallen by -$9.61 million (-37.65%). RNAZ annual CFF is now -37.65% below its all-time high of $25.52 million, reached on 31 December 2021.RNAZ Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$2.45 M
+$1.66 M+211.61%
01 September 2024
Summary:
TransCode Therapeutics quarterly cash flow from financing activities is currently $2.45 million, with the most recent change of +$1.66 million (+211.61%) on 01 September 2024. Over the past year, it has increased by +$1.47 million (+150.13%). RNAZ quarterly CFF is now -90.43% below its all-time high of $25.56 million, reached on 30 September 2021.RNAZ Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$10.30 M
-$4.94 M-32.44%
01 September 2024
Summary:
TransCode Therapeutics TTM cash flow from financing activities is currently $10.30 million, with the most recent change of -$4.94 million (-32.44%) on 01 September 2024. Over the past year, it has dropped by -$5.61 million (-35.28%). RNAZ TTM CFF is now -59.86% below its all-time high of $25.65 million, reached on 31 March 2022.RNAZ TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAZ Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +150.1% | -35.3% |
| 3 y3 years | -37.6% | +10000.0% | -59.6% |
| 5 y5 years | +3081.9% | - | - |
RNAZ Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -37.6% | >+9999.0% | -90.4% | +1183.6% | -59.9% | +4996.5% |
| 5 y | 5 years | -37.6% | >+9999.0% | -90.4% | +1183.6% | -59.9% | +4996.5% |
| alltime | all time | -37.6% | >+9999.0% | -90.4% | +1183.6% | -59.9% | +4996.5% |
TransCode Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.45 M(+211.6%) | $10.30 M(-32.4%) |
| June 2024 | - | $785.20 K(-87.1%) | $15.24 M(-26.8%) |
| Mar 2024 | - | $6.09 M(+522.3%) | $20.82 M(+30.8%) |
| Dec 2023 | $15.91 M(>+9900.0%) | $978.20 K(-86.8%) | $15.91 M(+5.0%) |
| Sept 2023 | - | $7.39 M(+16.2%) | $15.16 M(+101.0%) |
| June 2023 | - | $6.36 M(+438.6%) | $7.54 M(+538.6%) |
| Mar 2023 | - | $1.18 M(+422.9%) | $1.18 M(>+9900.0%) |
| Dec 2022 | $6000.00 | $225.80 K(-200.0%) | $6000.00(-102.9%) |
| Sept 2022 | - | -$225.80 K(<-9900.0%) | -$210.30 K(-100.8%) |
| June 2022 | - | $0.00(-100.0%) | $25.58 M(-0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $6000.00(-36.8%) | $25.65 M(+0.5%) |
| Dec 2021 | $25.52 M(+2185.4%) | $9500.00(-100.0%) | $25.52 M(+0.1%) |
| Sept 2021 | - | $25.56 M(>+9900.0%) | $25.49 M(<-9900.0%) |
| June 2021 | - | $78.80 K(-159.9%) | -$126.30 K(+736.4%) |
| Mar 2021 | - | -$131.60 K(+961.3%) | -$15.10 K(-101.4%) |
| Dec 2020 | $1.12 M(+123.3%) | - | - |
| Dec 2020 | - | -$12.40 K(-79.7%) | $1.12 M(-1.1%) |
| Sept 2020 | - | -$61.10 K(-132.2%) | $1.13 M(-5.1%) |
| June 2020 | - | $190.00 K(-81.0%) | $1.19 M(+19.0%) |
| Mar 2020 | - | $1.00 M | $1.00 M |
| Dec 2019 | $500.00 K | - | - |
FAQ
- What is TransCode Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly CFF year-on-year change?
- What is TransCode Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for TransCode Therapeutics?
- What is TransCode Therapeutics TTM CFF year-on-year change?
What is TransCode Therapeutics annual cash flow from financing activities?
The current annual CFF of RNAZ is $15.91 M
What is the all time high annual CFF for TransCode Therapeutics?
TransCode Therapeutics all-time high annual cash flow from financing activities is $25.52 M
What is TransCode Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of RNAZ is $2.45 M
What is the all time high quarterly CFF for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly cash flow from financing activities is $25.56 M
What is TransCode Therapeutics quarterly CFF year-on-year change?
Over the past year, RNAZ quarterly cash flow from financing activities has changed by +$1.47 M (+150.13%)
What is TransCode Therapeutics TTM cash flow from financing activities?
The current TTM CFF of RNAZ is $10.30 M
What is the all time high TTM CFF for TransCode Therapeutics?
TransCode Therapeutics all-time high TTM cash flow from financing activities is $25.65 M
What is TransCode Therapeutics TTM CFF year-on-year change?
Over the past year, RNAZ TTM cash flow from financing activities has changed by -$5.61 M (-35.28%)